In this interview, Frank Gleeson, co-founder and CEO of Satellos Bioscience, discusses the company’s pioneering approach to muscle regeneration. Satellos is leading the exploration of a novel mechanism called muscle stem cell polarity, which could revolutionise treatments for degenerative muscle conditions like DMD. Gleeson also highlights the potential of their lead drug SAT-3247, offering new hope for those affected by this debilitating disease.
Click here to read the article in this report on advances in stem cell research by Drug Target Review.
In The News
Discover